Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7894967rdf:typepubmed:Citationlld:pubmed
pubmed-article:7894967lifeskim:mentionsumls-concept:C0019196lld:lifeskim
pubmed-article:7894967lifeskim:mentionsumls-concept:C0279030lld:lifeskim
pubmed-article:7894967pubmed:issue1lld:pubmed
pubmed-article:7894967pubmed:dateCreated1995-4-27lld:pubmed
pubmed-article:7894967pubmed:abstractTextInterferon is effective for the treatment of hepatitis C infection in some patients. Although its effectiveness is established in patients with chronic hepatitis C infection, more work need to be done before it can be recommended for the treatment of patients with acute HCV infection. The currently recommended therapeutic regimen is 3 MU three times weekly, but higher dosages and longer duration of therapy may be more beneficial. Multiple factors including the degree of inflammation and fibrosis, HCV-RNA titer, and HCV genotype may influence the response to therapy. Therefore proper patient selection will improve response rate, and make interferon treatment more cost-effective. No controlled studies have yet evaluated the use of interferon in children with chronic HCV infection. Many questions are yet to be answered regarding interferon therapy in patients with chronic hepatitis C, thus we recommend all patients who belong to these categories be enrolled in clinical trials.lld:pubmed
pubmed-article:7894967pubmed:languageenglld:pubmed
pubmed-article:7894967pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7894967pubmed:citationSubsetIMlld:pubmed
pubmed-article:7894967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7894967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7894967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7894967pubmed:statusMEDLINElld:pubmed
pubmed-article:7894967pubmed:monthJanlld:pubmed
pubmed-article:7894967pubmed:issn1049-5118lld:pubmed
pubmed-article:7894967pubmed:authorpubmed-author:RakelaJJlld:pubmed
pubmed-article:7894967pubmed:authorpubmed-author:ZeinN NNNlld:pubmed
pubmed-article:7894967pubmed:issnTypePrintlld:pubmed
pubmed-article:7894967pubmed:volume6lld:pubmed
pubmed-article:7894967pubmed:ownerNLMlld:pubmed
pubmed-article:7894967pubmed:authorsCompleteYlld:pubmed
pubmed-article:7894967pubmed:pagination46-53lld:pubmed
pubmed-article:7894967pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:meshHeadingpubmed-meshheading:7894967-...lld:pubmed
pubmed-article:7894967pubmed:year1995lld:pubmed
pubmed-article:7894967pubmed:articleTitleInterferon therapy in hepatitis C.lld:pubmed
pubmed-article:7894967pubmed:affiliationDepartment of Medicine, Mayo Clinic and Foundation, Rochester, MN.lld:pubmed
pubmed-article:7894967pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7894967pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7894967lld:pubmed